Overexpression of an Immune Checkpoint (CD155) in Breast Cancer Associated with Prognostic Significance and Exhausted Tumor-Infiltrating Lymphocytes: A Cohort Study

Table 3

Cox hazard regression on association between CD155 expression and prognosis.

	CD155 expression		HRcrude	95% CI	HR^†	95% CI	HR^‡	95% CI
	Low expression	Overexpression ()
Disease-free survival, (%)
Relapse	6 (7.7)	15 (31.3)	5.41	1.93, 15.20	5.68	2.01, 16.02	13.93	2.82, 68.91
Survival	69 (88.5)	27 (56.3)
Overall survival, (%)
Death	6 (7.7)	9 (18.8)	3.74	1.25, 11.16	4.51	1.50, 13.63	5.47	1.42, 20.99
Survival	68 (87.2)	30 (62.5)

^†Further adjusting age. ^‡Further adjusting age, histological grade, and molecular subtype.